Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial

被引:0
作者
Jingjing Zhou
Weiwei Wang
Jian Yang
Xuequan Zhu
Lei Feng
Le Xiao
Gang Wang
机构
[1] Capital Medical University,National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital
[2] Capital Medical University,Mood Disorders Center, Beijing Anding Hospital
[3] Capital Medical University,Department of Psychiatry
[4] Beijing Institute for Brain Disorders,Center of Depression
来源
Trials | / 20卷
关键词
Scopolamine; Major depressive disorder; Efficacy; Randomized controlled trial;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 63 条
[1]  
Kessler RC(2013)The epidemiology of depression across cultures Annu Rev Public Health 34 119-138
[2]  
Bromet EJ(2013)Disability mediates the impact of common conditions on perceived health PLoS One 8 e65858-49
[3]  
Alonso J(2012)Recovery from depression Psychiatr Clin North Am 35 37-40
[4]  
Vilagut G(2006)Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am J Psychiatry 163 28-354
[5]  
Adroher ND(2000)Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 351-236
[6]  
Stotland NL(2007)Intravenous ketamine therapy in a patient with a treatment-resistant major depression Swiss Med Wkly 137 234-864
[7]  
Trivedi MH(2006)A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 856-438
[8]  
Rush AJ(2010)Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial Biol Psychiatry 67 432-1129
[9]  
Wisniewski SR(2006)Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch Gen Psychiatry 63 1121-2488
[10]  
Berman RM(2010)Scopolamine produces larger antidepressant and antianxiety effects in women than in men Neuropsychopharmacology 35 2479-67